Dialing Up Telehealth to Comprehensive Level Makes it More Effective: JAMA Internal Medicine Study

July 28, 2022

Results reported this week in JAMA Internal Medicine show a steeper decrease in HbA1C among people with poorly controlled type 2 diabetes who participated in a telehealth program that included telemonitoring, self-management support, medication management and services for depression. The comprehensive program cost about $1,500 more per year than the control program of standard telemonitoring and care coordination.

AMCP Nexus 2021 Updates on iGlarLixi in Type 2 Diabetes

March 01, 2022

An expert in endocrinology reviews updates from the AMCP Nexus 2021 conference on treatment persistence and adherence with iGlarLixi versus free-dose combinations of basal insulin and GLP-1 receptor agonists, and shares insight on future directions for disease management.

Fixed-Ratio Combinations for Type 2 Diabetes

January 27, 2022

Dr Jennifer Brigitte Green considers the patient selection for fixed-ratio combinations of basal insulin and GLP-1 receptor agonists among patients with type 2 diabetes and provides insight around Medicare patient access to insulin and injectable medications.

Clinical Inertia in Treatment of Type 2 Diabetes

January 27, 2022

Jennifer Brigitte Green, MD, discusses the reasoning behind clinical inertia in treating patients with type 2 diabetes and comments on achieving and maintaining glycemic control over an extended period.

Type 2 Diabetes: Considerations for Achieving Targeted Glycemic Control

January 20, 2022

Dr Jennifer Brigitte Green addresses clinical considerations for patients with type 2 diabetes who are not responding to their oral antidiabetic agents and discusses her strategy for insufficient target glycemic control with insulin regimens.

Tirzepatide Gets Middling Grade From ICER

January 06, 2022

The cost-effectiveness group say Lilly’s diabetes treatment should have an annual price of between $5,500 and $5,700. The FDA is expected to make a decision on whether to approve tirzepatide this year.